DSIP Peptide Spray

DSIP Intranasal Research & Scientific Overview

Jump to: Structure | Mechanism | Studies | Pharmacokinetics | Protocols | Limitations | Lead Researcher | References

DSIP Molecular Structure & Chemical Properties

Delta Sleep-Inducing Peptide (DSIP) is one of the most enigmatic neuropeptides in neuroscience research, first isolated in 1974 by the Swiss Schoenenberger-Monnier group from the cerebral venous blood of rabbits during electrically induced sleep. Over five decades of investigation have revealed that DSIP’s biological activity extends well beyond its original name, with research documenting effects across sleep architecture, stress regulation, neuroendocrine signaling, neuroprotection, and intranasal delivery to the central nervous system. What makes DSIP uniquely puzzling among studied neuropeptides is that neither its encoding gene nor a definitively identified receptor has been characterized – a gap that continues to drive scientific interest and debate. As a nine-amino-acid (nonapeptide) amphiphilic peptide, DSIP possesses both hydrophilic and lipophilic properties that contribute to its demonstrated ability to cross the blood-brain barrier, a characteristic that has made intranasal delivery a particularly active area of preclinical research.

Chemical Structure

[IMAGE PLACEHOLDER] Insert 2D chemical structure image here Image URL: https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=68816&t=l Alt text: DSIP delta sleep-inducing peptide 2D molecular structure diagram Source credit: PubChem Position: Center-aligned below “Chemical Structure” heading

2D molecular structure (Source: PubChem)

Technical Specifications

Property

Value

CAS Number

62568-57-4

Molecular Formula

C35H48N10O15 (subscripted)

Molecular Weight

848.8 g/mol

Amino Acid Sequence

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE)

Half-Life (Plasma/In Vitro)

~15 minutes in vitro (aminopeptidase-mediated); longer in vivo (carrier-bound)

Stability

Low in vitro stability; amphiphilic structure supports blood-brain barrier penetration

Solubility

Water-soluble; compatible with saline and phosphate-buffered saline solutions

Storage

Lyophilized: -20 degrees C; Reconstituted: 2-8 degrees C (stability varies by protocol)

The peptide’s amphiphilic character – derived from its mix of hydrophilic (Asp, Ser, Glu) and hydrophobic (Trp, Ala) residues – is thought to facilitate its passage through biological membranes, including the blood-brain barrier, which has made intranasal delivery routes of particular interest in preclinical research.

DSIP Mechanism of Action

DSIP does not operate through a single well-characterized receptor but instead appears to interact with multiple overlapping neurochemical systems. Current research identifies NMDA receptor modulation, GABA system interactions, MAPK cascade signaling, neuroendocrine axis modulation, and mitochondrial pathway effects as the primary mechanistic areas under investigation – making DSIP a multi-target peptide whose full pharmacological profile remains incompletely mapped.

Primary Cellular Pathways
NMDA Receptor Modulation – Excitatory Neurotransmission Control

Research indicates DSIP modulates N-methyl-D-aspartate (NMDA) receptor activity in the central nervous system, which may underlie both its neuroprotective and sleep-related effects[1]. Key findings include:

Decreased sensitivity of neuronal receptors to excitatory glutamate stimulation
Attenuation of excitotoxic processes, which may protect neurons under ischemic or stress conditions
NMDA interaction proposed as a primary CNS mechanism in multiple in vitro studies
Potential role in reducing calcium-mediated neuronal damage during hypoxia
GABAergic System Interactions – Inhibitory Neurotransmission

Studies have documented DSIP’s enhancement of GABA-activated currents in hippocampal and cerebellar neuron preparations[2]. This inhibitory interaction may contribute to observed reductions in motor activity and sleep-associated effects:

Enhancement of GABA-A receptor-mediated currents in specific brain regions
Simultaneous NMDA receptor blockade in cortical areas
Possible coordination of excitatory/inhibitory balance during sleep-wake transitions
Relationship to GABA-A receptor sites remains an area of active investigation
MAPK Cascade and GILZ Homology – Cellular Stress Response

Research suggests DSIP interacts with components of the mitogen-activated protein kinase (MAPK) cascade through structural homology with glucocorticoid-induced leucine zipper (GILZ), a protein that modulates inflammatory and stress responses[3]. This pathway involves:

Inhibition of Raf-1 activation, which reduces ERK phosphorylation
Glucocorticoid-regulated expression patterns
Implications for stress adaptation and anti-inflammatory activity
MAPK involvement also proposed in DSIP’s effects on lens epithelial cell function
Neuroendocrine Axis Modulation – Hormonal Regulation

Research has documented DSIP’s influence on multiple anterior pituitary hormone systems[4], including:

Decreased basal corticotropin (ACTH) levels and blockade of ACTH release
Stimulation of luteinizing hormone (LH) secretion
Stimulation of somatoliberin (GHRH) with corresponding somatotrophin (GH) release
Inhibition of somatostatin secretion
Modulation of pineal acetyltransferase (NAT) activity, which influences melatonin synthesis
Mitochondrial Oxidative Phosphorylation – Cellular Energy and Stress Protection

In vitro studies using rat brain mitochondria demonstrated that DSIP enhances the efficiency of oxidative phosphorylation under both normal and hypoxic conditions[5]. This mechanism includes:

Enhancement of the respiratory control ratio (RCR)
Increased rate of ADP phosphorylation
Complete prevention of hypoxia-induced reduction in mitochondrial respiratory activity at doses of 120 mcg/kg in rat studies
Proposed contribution to antioxidant and stress-protective activity in vivo

[CALLOUT BOX – Highlighted] Key Mechanistic Gap: Despite decades of research, no definitive DSIP receptor has been identified, and the peptide’s encoding gene remains unknown. Research findings rely heavily on DSIP-like immunoreactivity assays and analogue studies – meaning many attributed effects may involve related endogenous peptides rather than DSIP itself. [END CALLOUT BOX]

DSIP Nasal Research Applications & Key Findings
Sleep Architecture Research
Slow-Wave Sleep and EEG Studies

The peptide’s original discovery was based on its ability to enhance delta (slow-wave) EEG activity following intraventricular infusion in rabbits[6]. Subsequent multi-species studies found:

Delta and spindle EEG enhancement averaging 35% in neocortex and limbic cortex (rabbit models)
Slow-wave sleep (SWS) promotion demonstrated in rabbits, rats, mice, and dogs
In cats, REM sleep enhancement was more pronounced than SWS promotion
A U-shaped dose-response curve was characterized, with optimal effects at specific dose windows

Importantly, the sleep-promoting evidence for DSIP itself (as opposed to its structural analogues) is inconsistent. Stronger and more reproducible SWS effects have been demonstrated with synthesized DSIP analogues in rodent models[7].

Human Sleep Studies

A small number of controlled human studies have been conducted using intravenous DSIP administration[8]:

A double-blind crossover study in 6 healthy volunteers reported a 59% increase in total sleep time within 130 minutes of intravenous administration at 25 nmol/kg
Delayed effects included shortened sleep onset and improved sleep efficiency in subsequent nights
A separate double-blind study in 16 chronic insomnia patients showed statistically significant but weak improvements in sleep efficiency and latency compared to placebo
The insomnia study authors concluded short-term DSIP was “not likely to be of major therapeutic benefit” given the marginal effect sizes

These represent limited human data and do not constitute clinical trial evidence meeting modern standards.

Neuroprotection and Stroke Recovery Research
Intranasal DSIP in Ischemia Models

A 2021 study published in Molecules investigated intranasal DSIP administration in a rat middle cerebral artery occlusion (MCAO) stroke model[9]. Key findings included:

Intranasal delivery at 120 mcg/kg administered prior to and following occlusion
Significant recovery of motor coordination in rotarod testing over 21 days post-stroke
Brain infarction volume in DSIP-treated animals was smaller than in vehicle controls, though the difference did not reach statistical significance
Proposed mechanism involves rescue of motor cortex neurons and subcortical motor control structures
Ischemia-Reperfusion Injury

Research on DSIP and its analogue KND in ischemia-reperfusion models demonstrated[10]:

Reduction of myocardial infarction area by approximately 32% with DSIP treatment
DSIP analogue KND achieved up to 55% reduction in cardiac infarction area in rodent models
Brain infarction volume reduction in stroke models using intranasal analogue delivery
Antioxidant mechanisms proposed as a contributing protective pathway
Stress Response and Antistress Research
Cortisol and HPA Axis Studies

Multiple animal studies have examined DSIP’s influence on the hypothalamic-pituitary-adrenal (HPA) axis stress response[4]:

ACTH suppression and stress-hormone modulation observed in rodent models
Decreased stress-induced overproduction of free radicals in the CNS
Improved blood supply to the brain of stressed animals subjected to ischemic conditions
Stress-protective effects partially attributed to mitochondrial oxidative phosphorylation enhancement
Pain Modulation Research

Animal studies have documented antinociceptive effects of DSIP[11]:

Potent analgesic effects when administered intracerebroventricularly or intracisternally in mice
A small pilot clinical study in 7 patients with chronic pain (migraine, tinnitus, psychogenic pain) reported significant pain reduction in 6 of 7 participants following repeated intravenous administration
Simultaneous reduction in depressive symptoms observed in the pilot group

This pilot study is highly limited by small sample size and lack of placebo control, and cannot be interpreted as clinical evidence.

Addiction and Withdrawal Research

Animal and limited human pilot studies examined DSIP in withdrawal contexts[12]:

Research in opioid withdrawal models suggested DSIP reduced withdrawal symptom severity
Pilot studies in alcoholic and opiate-dependent patients reported improvements in withdrawal symptoms
Effects on monoamine oxidase A (MAO-A) activity proposed as a contributing mechanism
No large-scale or placebo-controlled human trials have been completed in this area

[CALLOUT BOX – Highlighted] Critical Research Context: While DSIP has been the subject of controlled human studies – more than many research peptides – the available human data involves very small samples, older methodology, and primarily intravenous administration. No peer-reviewed controlled trials have evaluated intranasal DSIP in humans. All mechanistic data on intranasal delivery derives from animal models. [END CALLOUT BOX]

DSIP Nasal Spray Pharmacokinetics & Metabolism
Absorption & Distribution – Intranasal Route

The intranasal delivery route has attracted considerable research interest for DSIP due to the peptide’s amphiphilic structure and demonstrated ability to cross the blood-brain barrier. Research demonstrates that both intravenous and intranasal administration result in meaningful CNS penetration, significantly increasing cortical delta wave activity in animal studies[9]. Nasal absorption bypasses first-pass hepatic metabolism and offers a direct pathway through olfactory neurons to the cerebrospinal fluid and brain parenchyma – a route of particular relevance for neuropeptide delivery. DSIP-like immunoreactive material has been detected in the hypothalamus, limbic system, pituitary, peripheral organs, and plasma of multiple mammalian species, indicating wide distribution following systemic or central delivery.

Metabolism & Elimination

DSIP presents a significant pharmacokinetic paradox. In vitro studies reveal a plasma half-life of approximately 15 minutes, with degradation driven by a specific aminopeptidase-like enzyme[3]. Yet biological effects in animal models persist well beyond this rapid clearance window. Research suggests two explanations: first, DSIP may complex with endogenous carrier proteins in vivo that protect it from enzymatic degradation; second, the peptide may exist as a component of a larger precursor molecule that has not yet been characterized. Key metabolic findings include:

In vitro half-life of approximately 15 minutes due to aminopeptidase activity
In vivo behavior strongly suggests carrier protein binding extends functional half-life
Glucocorticoid regulation of DSIP levels has been proposed based on GILZ homology evidence
Metabolic pathways remain incompletely characterized
Excretion Pathways

The excretory pharmacokinetics of DSIP have not been fully characterized in published research[2]. Available evidence indicates:

Likely renal elimination of degradation products following peptide cleavage
Hepatic contribution to metabolic clearance possible but unconfirmed
DSIP-like material detected in human breast milk, suggesting peripheral distribution and secretory clearance pathways
No accumulation data from chronic dosing studies are available in the published literature
DSIP Research Protocols & Administration
Dosing in Published Research

Preclinical studies have employed a range of DSIP doses depending on species, model type, and route of administration:

Rat studies (intraperitoneal/intranasal): 120 mcg/kg is a common dose used in neuroprotection and stroke models
Rat studies (stress/mitochondria): 120 mcg/kg (intraperitoneal) used in hypoxia and oxidative stress protocols
Rabbit studies (intraventricular): 6 nmol/kg used in original EEG/sleep characterization studies
Human studies (intravenous): 25 nmol/kg used in sleep and insomnia research protocols

Important: These are experimental doses used in animal studies and cannot be extrapolated to other species due to significant differences in metabolism, receptor expression, pharmacokinetics, blood-brain barrier permeability, and peptide degradation rates across species.

Administration Routes in Research

Multiple delivery routes have been investigated across DSIP research:

Intranasal/nasal – Used in recent neuroprotection and stroke recovery studies in rats; allows direct olfactory-to-CNS transport potential; highlighted in stroke recovery research as the primary delivery route of interest
Intraventricular (intracerebroventricular) – Used in original sleep-induction and EEG characterization studies in rabbits and rodents
Intraperitoneal injection – Common in rodent stress, mitochondria, and antioxidant research protocols
Intravenous infusion – Used in human sleep and insomnia studies; slow infusion protocol described in controlled trials
Intracisternal – Used in pain modulation studies in mice
Subcutaneous injection – Referenced in some peptide research protocols
Common Model Organisms

DSIP has been studied across multiple preclinical species:

Rabbits – Primary original discovery model; intraventricular and sleep characterization studies
Rats (Wistar, Sprague-Dawley, C57Bl/6) – Dominant model for stroke, neuroprotection, stress, and mitochondrial studies; most intranasal research
Mice – Used in ischemia-reperfusion, pain, and longevity studies
Dogs – Referenced in early pharmacokinetic and sleep characterization research
Cats – Used in early sleep staging studies where REM effects dominated
Cell cultures – Hippocampal and cerebellar neuron preparations for receptor interaction studies
Research Limitations & Regulatory Status
Critical Gaps in Current Evidence

Despite nearly 50 years of research, DSIP faces fundamental unresolved questions that significantly limit the interpretability of published findings and preclude clinical application.

Lack of Identified Gene and Receptor

The most scientifically unusual gap in DSIP research is the continued absence of an identified encoding gene or specific receptor:

No DSIP gene has been isolated in any species, including those where the peptide was originally discovered
No specific DSIP receptor has been characterized or cloned
It remains unclear whether DSIP itself is the primary bioactive agent or a proxy for an unidentified endogenous DSIP-like peptide
Many attributed effects may be mediated by structurally related endogenous peptides rather than DSIP directly
Inconsistent Human and Clinical Data

Human study findings are limited in scope and reproducibility:

All controlled human studies used intravenous administration; no peer-reviewed controlled trials of intranasal DSIP in humans exist
Human sleep studies produced weak, partially inconsistent effect sizes
Pilot studies in pain and withdrawal were very small (6-7 patients) and lacked placebo controls
No modern Phase I, II, or III clinical trials have been registered or published
Long-Term Safety Considerations

Critical safety questions remain entirely unanswered:

Chronic effects of DSIP exposure have not been studied even in animal models beyond short experimental windows
Interaction potential with medications, sleep aids, and anesthetic agents uncharacterized (one human study reported unexpected cardiovascular effects with isoflurane co-administration)
Long-term neuroendocrine effects of ACTH suppression and LH stimulation unstudied
Reproductive and developmental toxicity not investigated
Regulatory & Competitive Sport Status
FDA Position

DSIP has not received FDA approval for any indication in humans or animals:

Not approved for any therapeutic use in humans or animals
Not recognized as GRAS (Generally Recognized as Safe)
Not approved for compounding for human administration in the United States
Classified as a research-use-only substance
WADA Status

DSIP does not currently appear on the World Anti-Doping Agency’s prohibited substance list by name; however:

WADA’s S0 category prohibits non-approved pharmacological substances with potential performance-enhancing effects
Any peptide with potential hormonal effects (GH stimulation, LH stimulation) may fall under existing prohibited substance categories
Athletes and researchers in sport contexts should consult current WADA documentation directly before any research involving competitive athletes

Research Classification: DSIP is available only for laboratory research use. It is not intended for human consumption, medical use, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

Lead Researcher Spotlight
Professor G.A. Schoenenberger, MD, PhD

Department of Research/Neuropharmacology University of Basel, Basel, Switzerland

Professor G.A. Schoenenberger was the lead investigator in the Schoenenberger-Monnier group responsible for isolating and characterizing DSIP from rabbit cerebral venous blood, first reported in a landmark 1977 paper in the Proceedings of the National Academy of Sciences. His laboratory conducted the foundational work establishing DSIP’s amino acid sequence, synthesizing the peptide, and demonstrating its EEG-modifying effects across multiple animal models. Schoenenberger subsequently authored extensive reviews characterizing DSIP’s multivariate properties and exploring its potential role as a neurohumoral programming substance, providing the conceptual framework for decades of subsequent research.

Key research contributions from Schoenenberger’s work include:

Original isolation and sequencing of DSIP from rabbit cerebral venous blood
Synthesis of DSIP and structural analogues with characterization of dose-response relationships
Early human sleep studies using intravenous DSIP in normal volunteers and chronic insomnia patients
Characterization of DSIP’s multivariate neuromodulatory functions across species
Frameworks for understanding DSIP as a potential “psychophysiological programming substance”

Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to DSIP research. Cenexa Labs has no affiliation with Professor Schoenenberger or the University of Basel, and this information does not constitute an endorsement of any products or services.

References
Koplik, E. (2008). Delta sleep-inducing peptide and Deltaran: Potential approaches to antistress protection. Neuroscience and Behavioral Physiology, 38(1), 953-957. PubMed

Graf, M.V., & Kastin, A.J. (1984). Delta-sleep-inducing peptide (DSIP): A review. Neuroscience & Biobehavioral Reviews, 8(1), 83-93. PubMed

Kovalzon, V.M., & Strekalova, T.V. (2006). Delta sleep-inducing peptide (DSIP): A still unresolved riddle. Journal of Neurochemistry, 97(2), 303-309. PubMed

Schoenenberger, G.A. (1984). Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). European Neurology, 23(5), 321-345. PubMed

Sudakov, K.V., Coghlan, J.P., Kotov, A.V., Salieva, R.M., Polyntsev, Y.V., & Koplik, E.V. (1995). Delta-sleep-inducing peptide sequels in the mechanisms of resistance to emotional stress. Annals of the New York Academy of Sciences, 771, 240-251. PubMed

Schoenenberger, G.A., Maier, P.F., Tobler, H.J., Wilson, K., & Monnier, M. (1978). The delta EEG (sleep)-inducing peptide (DSIP). XI. Amino-acid analysis, sequence, synthesis and activity of the nonapeptide. Pflugers Archiv: European Journal of Physiology, 376(2), 119-129. PubMed

Schneider-Helmert, D., Gnirss, F., Monnier, M., Schenker, J., & Schoenenberger, G.A. (1981). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. European Neurology, 20(5), 396-405. PubMed

Schneider-Helmert, D. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology, 25(3), 129-133. PubMed

Tukhovskaya, E.A., Ismailova, A.M., Slivin, M.A., Khokhlova, O.N., Fabrikant, I.G., Slinkin, M.A., Vanchakova, N.V., Murashev, A.N., & Balaban, P.M. (2021). Delta sleep-inducing peptide recovers motor function in SD rats after focal stroke. Molecules, 26(17), 5173. PubMed

Tukhovskaya, E.A., Yukin, A.Y., Khokhlova, O.N., Murashev, A.N., & Vitek, M.P. (2021). DSIP-like KND peptide reduces brain infarction in C57Bl/6 and reduces myocardial infarction in SD rats when administered during reperfusion. Biomedicines, 9(4), 407. PubMed

Schoenenberger, G.A. (1984). Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. European Neurology, 23(5), 372-385. PubMed

Backmund, M., Meyer, K., Rothenhaeusler, H.B., & Soyka, M. (2003). Opioid detoxification with delta sleep-inducing peptide: a placebo-controlled trial. Journal of Clinical Psychopharmacology, 23(3), 305-308. PubMed

Mu, X., Qu, L., Yin, L., Wang, L., Liu, X., & Liu, D. (2024). Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Frontiers in Pharmacology, 15, 1439536. PubMed

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. DSIP is intended for laboratory research use only.